23-Mar-2026
Cencora to Acquire EyeSouth Retina Business for Expansion
TipRanks (Mon, 23-Mar 8:00 AM ET)
Business Wire (Mon, 23-Mar 7:00 AM ET)
Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Novartis in focus
Seeking Alpha News (Sun, 22-Mar 9:05 AM ET)
Cencora Announces Financial Leadership Transition
Business Wire (Tue, 17-Mar 8:30 AM ET)
Covetrus and MWI Animal Health to Merge
Business Wire (Wed, 18-Feb 7:00 AM ET)
Cencora Closes $3.0 Billion Senior Notes Offering
Business Wire (Fri, 13-Feb 4:15 PM ET)
Business Wire (Tue, 10-Feb 5:15 PM ET)
Cencora Raises Operating Income Guidance After Strong First Quarter and OneOncology Acquisition
Market Chameleon (Wed, 4-Feb 4:41 AM ET)
Cencora Reports Fiscal 2026 First Quarter Results
Business Wire (Wed, 4-Feb 6:30 AM ET)
Cencora Elects Ellen Cooper to Its Board of Directors
Business Wire (Thu, 22-Jan 7:30 AM ET)
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Cencora trades on the NYSE stock market under the symbol COR.
As of March 23, 2026, COR stock price declined to $320.61 with 1,216,008 million shares trading.
COR has a beta of 0.05, meaning it tends to be less sensitive to market movements. COR has a correlation of 0.00 to the broad based SPY ETF.
COR has a market cap of $62.37 billion. This is considered a Large Cap stock.
Last quarter Cencora reported $86 billion in Revenue and $4.08 earnings per share. This fell short of revenue expectation by $-161 million and exceeded earnings estimates by $.03.
The top ETF exchange traded funds that COR belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
COR has outperformed the market in the last year with a return of +20.6%, while the SPY ETF gained +17.9%. However, in the most recent history, COR shares have underperformed the stock market with its stock returning -5.8% in the last 3 month period and -10.6% for the last 2 week period, while SPY has returned -3.4% and -2.3%, respectively.
COR support price is $321.63 and resistance is $332.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COR shares will trade within this expected range on the day.
